- A166 (ASCO Summary #1024) is a 3rd era antibody drug conjugate (ADC) towards HER2-positive breast most cancers with Levena’s proprietary tubulin inhibitor Duo-5 toxin, cleavable linker and site-specific Ok-Lock™ conjugation chemistry.
- On this Section 1 Research, A166 demonstrated a manageable security profile and excessive stability in circulation with a lot decrease acute hematological and gastrointestinal toxicities in comparison with business merchandise.
- A166 has additionally demonstrated promising antitumor exercise with clinically significant responses in closely pretreated topics with HER2-positive breast most cancers. At a dose of 6.0 mg/kg, A166 demonstrated an 71.4% ORR as in comparison with 60.9% ORR from its main competitor DS-8201 at 5.4 mg/kg.
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) as we speak introduced that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun”), a license and improvement companion, will current posters at this 12 months’s American Society of Medical Oncology (ASCO) assembly to be held June 5-6, 2021, releasing Section 1 information for its HER2-ADC, A166. To generate this site-specific third era antibody drug conjugate (ADC), Kelun partnered with Levena Biopharma, an entirely owned subsidiary of Sorrento, which supplied the patent-protected applied sciences for the era and manufacturing of A166, together with (1) a proprietary small molecule toxin, Duostatin-5, a tubulin inhibitor, (2) Ok-Lock, a site-specific conjugation expertise and (3) an enzymatically cleavable linker. In comparison with its business rivals, A166 demonstrated a greater security profile within the preliminary research and probably higher efficacy, as proven within the general response price (ORR) of 71.4% (A166) at 6.0 mg/kg vs DS-8201, which has an ORR of 60.9% (DS-8201) at 5.4 mg/kg.
Medical Trial Info:
Medical Trial Registry Quantity:
J Clin Oncol 39, 2021 (suppl 15; abstr 1024)
About Sorrento Therapeutics, Inc.
Sorrento is a scientific stage, antibody-centric, biopharmaceutical firm growing new therapies to deal with cancers and COVID-19. Sorrento’s multimodal, multipronged method to preventing most cancers is made potential by its intensive immuno-oncology platforms, together with key belongings corresponding to totally human antibodies (“G-MAB™ library”), scientific stage immuno-cellular therapies (“CAR-T”, “DAR-T™”), antibody-drug conjugates (“ADCs”), and scientific stage oncolytic virus (“Seprehvir™”). Sorrento can also be growing potential antiviral therapies and vaccines towards coronaviruses, together with COVIGUARD™, COVI-AMG™, COVISHIELD™, Gene-MAb™, COVI-MSC™ and COVIDROPS™; and diagnostic take a look at options, together with COVITRACK™, COVISTIX™ and COVITRACE™.
Sorrento’s dedication to life-enhancing therapies for sufferers can also be demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid ache administration small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a broadly used corticosteroid for epidural injections to deal with lumbosacral radicular ache, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the remedy of post-herpetic neuralgia. RTX has accomplished a Section IB trial for intractable ache related to most cancers and a Section 1B trial in osteoarthritis sufferers. SEMDEXA is in a pivotal Section 3 trial for the remedy of lumbosacral radicular ache, or sciatica. ZTlido® was permitted by the FDA on February 28, 2018.
For extra info go to www.sorrentotherapeutics.com.
This press launch and any statements made for and through any presentation or assembly include forward-looking statements associated to Sorrento Therapeutics, Inc., underneath the protected harbor provisions of Part 21E of the Non-public Securities Litigation Reform Act of 1995 and topic to dangers and uncertainties that might trigger precise outcomes to vary materially from these projected. Ahead-looking statements embody statements concerning the potential security profile and/or therapeutic efficacy of A166, together with the demonstrated stability and/or discount in acute toxicities as in comparison with business merchandise; and the conduct of scientific trials of A166. Dangers and uncertainties that might trigger our precise outcomes to vary materially and adversely from these expressed in our forward-looking statements, embody, however are usually not restricted to: dangers associated to Sorrento’s applied sciences and prospects with respect to A166, together with, however not restricted to dangers associated to scientific improvement dangers, together with dangers within the progress, timing, price, and outcomes of scientific trials and product improvement applications; danger of difficulties or delays in acquiring regulatory approvals; dangers that scientific research outcomes could not meet all or any endpoints of a scientific research and that any information generated from such research could not help a regulatory submission or approval; dangers that prior take a look at, research and trial outcomes will not be replicated in future research and trials; dangers of producing and supplying drug product; dangers associated to leveraging the experience of its staff, subsidiaries, associates and companions to help Sorrento within the execution of its therapeutic antibody product candidate methods; dangers associated to the worldwide impression of COVID-19; and different dangers which are described in Sorrento’s most up-to-date periodic reviews filed with the Securities and Change Fee, together with Sorrento’s Annual Report on Kind 10-Ok for the 12 months ended December 31, 2020, and subsequent Quarterly Studies on Kind 10-Q filed with the Securities and Change Fee, together with the danger elements set forth in these filings. Traders are cautioned to not place undue reliance on these forward-looking statements, which communicate solely as of the date of this launch and we undertake no obligation to replace any forward-looking assertion on this press launch besides as required by legislation.
Media and Investor Relations Contact
Alexis Nahama, DVM (SVP Company Improvement)
Electronic mail: [email protected]
Sorrento® and the Sorrento brand are registered logos of Sorrento Therapeutics, Inc.
G-MAB™, DAR-T™, SOFUSA™, COVIGUARD™, COVI-AMG™, COVISHIELD™, Gene-MAb™, COVIDROPS™, COVI-MSC™, COVITRACK™, COVITRACE™ and COVISTIX™ are logos of Sorrento Therapeutics, Inc.
SEMDEXA™ is a trademark of Semnur Prescribed drugs, Inc.
ZTlido® is a registered trademark owned by Scilex Prescribed drugs Inc.
All different logos are the property of their respective homeowners.
©2021 Sorrento Therapeutics, Inc. All Rights Reserved.